Piper Sandler Raises Moderna (MRNA) Price Target to $230

By TradeTexts Research Desk Oct 26, 2026, 11:15 AM EDT

Key Points

Piper Sandler increased its price target for Moderna, Inc. from $167 to $230, reflecting a strong outlook for the company.
Piper Sandler's $230 price target implies 16.11% upside from Moderna, Inc.'s ($MRNA) current $198.09 share price.
As of October 26, 2026, Moderna's stock recently traded around $198.09, which is above its event close of $197.30.
The average target price from analysts for Moderna is $135.84, indicating room for growth compared to the new target set by Piper Sandler.

Get Moderna text alerts

We text you when insiders, Congress, analysts or big funds move on $MRNA.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Moderna, Inc. alert may contain errors. Disclosures

On October 26, 2026, Piper Sandler raised its price target on Moderna, Inc. (MRNA) to $230 from $167, maintaining an Overweight rating. This adjustment shows the firm’s positive outlook on the biotechnology company. The information comes from Piper Sandler's research note published on the same day.

Piper Sandler's new target indicates a significant increase in their expectations for the stock's future performance. The updated target reflects a strong belief in Moderna's potential, especially as it continues to develop its messenger RNA medicines.

MRNA Moderna, Inc.

$200.10 +548.41% year to date

Daily close · Oct 23, 2026

Analyst rating track record

Piper Sandler vs. the S&P 500

YTD return +4.50% hypothetical

All-time return +4.50% S&P 500 +2.05%

vs. S&P 500 +2.45% ahead of the index

Hypothetical returns from Piper Sandler's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Moderna, Inc.

BAILLIE GIFFORD & CO reduced its stake by 1,778,708 shares, ending with 18,206,778 shares worth about $3.6 billion. Theleme Partners LLP slightly increased its holdings by 9,657 shares, bringing its total to 8,057,571 shares valued at approximately $1.6 billion. This activity shows a mix of sentiment among other institutional investors regarding Moderna's stock.

Moderna, Inc. Stock Down 2.2%

Moderna's stock recently traded around $198.09, which is above its event close of $197.30 on October 26, 2026. The shares are currently above their 50-day moving average of $171.15 and significantly above the 200-day average of $82.16. However, the stock is still about 22.2% below its 52-week high of $254.48.

12-month forecast

$MRNA price target

Moderna, Inc. daily closes and this analyst's $230 target. Not advice.

Recent Earnings

Moderna reported trailing twelve-month revenue of $2.23 billion, with a year-over-year revenue growth of 2.1%. The company's next earnings report is scheduled for November 6, 2026. These figures suggest that while revenue is growing, the overall profitability remains a challenge with a negative net margin of 141.4%.

Insider Buying and Selling at Moderna, Inc.

Since August, several insiders have sold shares. CEO Stephane J Bancel sold 499,246 shares on August 5, 2026, valued at approximately $28.7 million. Officer Shannon Thyme Klinger sold 3,471 shares on September 1, 2026, for around $485,766. CFO James M Mock sold 34,836 shares on September 10, 2026, for about $4.7 million. President Stephen Hoge sold 80,575 shares on September 15, 2026, valued at approximately $11.7 million. This activity came before Piper Sandler's recent rating update.

Analysts Set New Price Targets

On October 26, 2026, Piper Sandler reiterated its Overweight rating for Moderna, raising its price target to $230 from $167. The consensus among analysts is that the average price target stands at around $135.84, with 19 analysts contributing to this outlook. Other recent ratings include a downgrade to Sell by Citigroup with a target of $80 and a hold rating from TD Cowen with a target of $90.

About Moderna, Inc.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in messenger RNA medicines. Its innovative approach to medicine is crucial in addressing various health challenges, particularly in the vaccine space. The recent price target increase by Piper Sandler reflects confidence in its ongoing projects and market potential.

Bottom Line

Investors should keep an eye on Moderna's upcoming earnings report on November 6, 2026, for further insights into the company's performance. With the recent price target adjustment by Piper Sandler, it will be interesting to see how the market reacts in the coming days.